ライフサイエンスコーパス: neoadjuvant chemotherapy

1 elp predict the response of breast cancer to neoadjuvant chemotherapy.

2 disease (POST-TEXT) stages III and IV after neoadjuvant chemotherapy.

3 outcomes in a node-positive cohort receiving neoadjuvant chemotherapy.

4 he Ki67 was > 10%, patients were switched to neoadjuvant chemotherapy.

5 asets on breast cancer patients who received neoadjuvant chemotherapy.

6 deally to no visible disease) should receive neoadjuvant chemotherapy.

7 surgery and axillary dissection (ALND) after neoadjuvant chemotherapy.

8 surgery reduces the FNR of SLN surgery after neoadjuvant chemotherapy.

9 performed at baseline and after 2 cycles of neoadjuvant chemotherapy.

10 complete response (pCR) is not reached after neoadjuvant chemotherapy.

11 10 mL), both administered every 3 weeks with neoadjuvant chemotherapy.

12 hemotherapy was known, 27,300 (23%) received neoadjuvant chemotherapy.

13 assessment of the pathologic response after neoadjuvant chemotherapy.

14 ith node-positive breast cancer treated with neoadjuvant chemotherapy.

15 d complete response or partial response with neoadjuvant chemotherapy.

16 to define the extent of breast cancer before neoadjuvant chemotherapy.

17 and included consecutive patients treated by neoadjuvant chemotherapy.

18 e in baseline characteristics was the use of neoadjuvant chemotherapy.

19 s of breast-conserving surgery and pCR after neoadjuvant chemotherapy.

20 cluded patients, 400 patients (68%) received neoadjuvant chemotherapy.

21 tients suffering from PRMS were treated with neoadjuvant chemotherapy.

22 or single anti-HER2 treatment in addition to neoadjuvant chemotherapy.

23 administration with anthracycline and taxane neoadjuvant chemotherapy.

24 egative (n = 38) breast cancers who received neoadjuvant chemotherapy.

25 ry before and those undergoing surgery after neoadjuvant chemotherapy.

26 derwent surgery first and 652 (22%) received neoadjuvant chemotherapy.

27 patients undergoing surgery before or after neoadjuvant chemotherapy.

28 -FDG PET for early prediction of response to neoadjuvant chemotherapy.

29 with either upfront surgery or surgery after neoadjuvant chemotherapy.

30 gulated in residual tumor cells that survive neoadjuvant chemotherapy.

31 asurements were acquired before the start of neoadjuvant chemotherapy.

32 tted in selected women with good response to neoadjuvant chemotherapy.

33 f pathologic response in subjects undergoing neoadjuvant chemotherapy.

34 educed E-cadherin expression in tumors after neoadjuvant chemotherapy.

35 ndividual patients with breast cancer before neoadjuvant chemotherapy.

36 this stage for the selection of patients for neoadjuvant chemotherapy.

37 r to develop and test genomic predictors for neoadjuvant chemotherapy.

38 e AJCC staging system for patients receiving neoadjuvant chemotherapy.

39 ith "M1" low tumors, or with the response to neoadjuvant chemotherapy.

40 195 patients undergoing PAR (48.7%) received neoadjuvant chemotherapy.

41 regular diet for 3 days prior to and during neoadjuvant chemotherapy.

42 t present with any pathologic response after neoadjuvant chemotherapy.

43 Cyclin E independently predicted response to neoadjuvant chemotherapy.

44 ing EVs of breast cancer patients undergoing neoadjuvant chemotherapy.

45 ving pathological complete response (pCR) to neoadjuvant chemotherapy.

46 nced intraocular retinoblastoma treated with neoadjuvant chemotherapy.

47 and in 28 women (31 index malignancies) with neoadjuvant chemotherapy.

48 breast cancer who had residual disease after neoadjuvant chemotherapy.

49 or tripe negative breast cancer resistant to neoadjuvant chemotherapy.

50 ns of BRCA score with genome instability and neoadjuvant chemotherapy.

51 c survival outcomes in patients treated with neoadjuvant chemotherapy.

52 negative tumors resected from patients after neoadjuvant chemotherapy.

53 loc 2-field lymphadenectomy in patients post neoadjuvant chemotherapy.

54 There were 84 (75.4%) patients who received neoadjuvant chemotherapy, 105 (89%) simultaneous venous

55 After one cycle of neoadjuvant chemotherapy, a 34% reduction in the (13)C-l

56 ake at baseline on PET/CT and response after neoadjuvant chemotherapy according to criteria from the

57 rwent surgery before and those who underwent neoadjuvant chemotherapy after surgery.

58 ients were randomized to receive adjuvant or neoadjuvant chemotherapy alone (control group) or chemot

59 am with a minimisation technique, to receive neoadjuvant chemotherapy alone or with 1 year of trastuz

60 2-negative disease was included and received neoadjuvant chemotherapy alone.

61 nts with rectal cancer who were treated with neoadjuvant chemotherapy also received postoperative sys

62 ten recurs despite aggressive treatment with neoadjuvant chemotherapy and (radical) cystectomy.

63 pression is associated with poor response to neoadjuvant chemotherapy and an increased risk of relaps

64 lly advanced unresectable PDAC receiving SOC neoadjuvant chemotherapy and chemoradiation.

65 Radiological response rates after neoadjuvant chemotherapy and chemoradiotherapy were 74%

66 ith 1 year of trastuzumab (concurrently with neoadjuvant chemotherapy and continued after surgery).

67 ly changes in blood flow (BF) in response to neoadjuvant chemotherapy and evaluated with (15)O-water

68 c invasive breast cancer who did not receive neoadjuvant chemotherapy and factors associated with a l

69 ase in the breast or axilla after completing neoadjuvant chemotherapy and HER2-targeted therapy were

70 in 71 women (79 index malignancies) without neoadjuvant chemotherapy and in 28 women (31 index malig

71 stage IIIC or IV epithelial ovarian cancer, neoadjuvant chemotherapy and interval cytoreduction are

72 test cohort (TC) of 62 patients treated with neoadjuvant chemotherapy and interval debulking surgery.

73 of breast cancer response after one cycle of neoadjuvant chemotherapy and may improve response predic

74 n was strongly associated with resistance to neoadjuvant chemotherapy and poor clinical outcomes.

75 15 mg/kg, every 3 weeks for six cycles) with neoadjuvant chemotherapy and postoperatively for ten dos

76 with limited metastatic disease who received neoadjuvant chemotherapy and proceeded to surgery showed

77 tant high-risk feature, and an indicator for neoadjuvant chemotherapy and prognosis.

78 idelines recommend that patients who receive neoadjuvant chemotherapy and radiation for locally advan

79 n prostate cancer specimens before and after neoadjuvant chemotherapy and radical prostatectomy.

80 ith clinical stages II to III rectal cancer, neoadjuvant chemotherapy and selective radiation does no

81 ith pathologic complete response (pCR) after neoadjuvant chemotherapy and to explore the association

82 Preoperative (neoadjuvant) chemotherapy and radiotherapy are more effe

83 Most (72%) always recommend neoadjuvant chemotherapy, and 65% prefer FOLFIRINOX.

84 ucibility and ability to monitor response to neoadjuvant chemotherapy, and determine surgical resecta

85 n other methods of assessing the response to neoadjuvant chemotherapy, and is helpful in identifying

86 r who had a clinical complete response after neoadjuvant chemotherapy, and who were subsequently mana

87 with three different types of commonly used neoadjuvant chemotherapies: anthracycline alone, anthrac

88 ave extensive residual invasive cancer after neoadjuvant chemotherapy are at a high risk of recurrenc

89 Predictive biomarkers for tumor response to neoadjuvant chemotherapy are needed in breast cancer.

90 hologic response and lymph node status after neoadjuvant chemotherapy are prognostic in patients trea

91 internal cohort of 804 patients treated with neoadjuvant chemotherapy at our institution from 2003 to

92 on patients with breast cancer treated with neoadjuvant chemotherapy at The University of Texas MD A

93 positive breast cancer patients treated with neoadjuvant chemotherapy, BCSS and OS were associated wi

94 Neoadjuvant chemotherapy before cystectomy confers a sur

95 or patients with gastric cancer treated with neoadjuvant chemotherapy before surgery for the accurate

96 Neoadjuvant chemotherapy before surgery improves surviva

97 Ten patients completed neoadjuvant chemotherapy before surgery.

98 tly treated with surgery, while 28 underwent neoadjuvant chemotherapy beforehand.

99 Patients who are downstaged by neoadjuvant chemotherapy benefit from reduced rates of l

100 Patients receiving neoadjuvant chemotherapy between 1997 and 2005 were iden

101 ncers who underwent breast MR imaging before neoadjuvant chemotherapy between April 10, 2008, and Mar

102 s, MYC signaling did not predict response to neoadjuvant chemotherapy but was associated with poor pr

103 almos and patients with risk of abandonment, neoadjuvant chemotherapy can be effective when followed

104 Early metabolic change during neoadjuvant chemotherapy can predict pathologic response

105 and 3 patients with untreated breast cancer (neoadjuvant chemotherapy candidates, tumor size > 2 cm)

106 MD Anderson taxane plus anthracycline-based neoadjuvant chemotherapy cohort (MD Anderson-NeoACT; n=5

107 ve-ACT; n=697), the Nottingham anthracycline neoadjuvant chemotherapy cohort (Nottingham-NeoACT; n=20

108 Neoadjuvant chemotherapy comprising cisplatin, doxorubic

109 of biopsy-proven node-positive patients with neoadjuvant chemotherapy could safely permit sentinel ly

110 r results suggest that the reduction after 2 neoadjuvant chemotherapy cycles of the metabolically act

111 After 2 neoadjuvant chemotherapy cycles, the reduction of each p

112 sophagogastric junction adenocarcinoma after neoadjuvant chemotherapy determines prognosis rather tha

113 ment consisted of a multimodal protocol with neoadjuvant chemotherapy, enucleation, orbital external-

114 tients in ACOSOG Z1031B who were switched to neoadjuvant chemotherapy experienced a pCR (5.7%; 95% CI

115 Patients with downstaged tumors after neoadjuvant chemotherapy experienced improved survival c

116 ly 8-20% of breast cancer patients receiving neoadjuvant chemotherapy fail to achieve a measurable re

117 For resectable lesions, studies on neoadjuvant chemotherapy failed to convincingly demonstr

118 hort of patients from 2011-2017 treated with neoadjuvant chemotherapy followed by chemoradiation and

119 nd clinically relevant survival benefit, and neoadjuvant chemotherapy followed by definitive local th

120 Platinum-based neoadjuvant chemotherapy followed by delayed primary sur

121 omen recruited to ICON8 who were planned for neoadjuvant chemotherapy followed by DPS and had RECIST

122 sponses in patients receiving platinum-based neoadjuvant chemotherapy followed by DPS in the ICON8 tr

123 w-up was 29.5 months (IQR 15.6-54.3) for the neoadjuvant chemotherapy followed by DPS population.

124 in ICON8, of whom 779 (50%) were planned for neoadjuvant chemotherapy followed by DPS.

125 atment with a uniform protocol consisting of neoadjuvant chemotherapy followed by enucleation, adjuva

126 All patients received neoadjuvant chemotherapy followed by enucleation, radiot

127 primary treatment: either primary surgery or neoadjuvant chemotherapy followed by interval surgery.

128 The patient was advised to undergo neoadjuvant chemotherapy followed by radical cystectomy

129 He received four cycles of cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy

130 The current standard of care is neoadjuvant chemotherapy followed by radical cystectomy,

131 rrent standard of care for these patients is neoadjuvant chemotherapy followed by radical cystoprosta

132 al for patients with gastric carcinoma after neoadjuvant chemotherapy followed by surgery.

133 nd 298, respectively), a cohort who received neoadjuvant chemotherapy followed by tamoxifen and/or ar

134 al junction adenocarcinoma who have received neoadjuvant chemotherapy followed by transthoracic esoph

135 acyclines and taxanes have been the standard neoadjuvant chemotherapies for breast cancer in the past

136 ve the potential to help predict response to neoadjuvant chemotherapy for breast cancer as early as c

137 carboplatin (PTX/CBP) regimen, an effective neoadjuvant chemotherapy for breast cancer patients.

138 Neoadjuvant chemotherapy for breast cancer provides crit

139 mental regimens in combination with standard neoadjuvant chemotherapy for breast cancer.

140 anthracyclines could improve pCR in standard neoadjuvant chemotherapy for breast cancer.

141 RECIST and GCIG CA125 responses to neoadjuvant chemotherapy for epithelial ovarian cancer s

142 to first-line therapy, 31 patients received neoadjuvant chemotherapy for localized/locally advanced

143 To evaluate the risk of neoadjuvant chemotherapy for surgical morbidity after ma

144 T0-4N1-2 breast cancer patients treated with neoadjuvant chemotherapy from 2009 to 2011.

145 her increasing the duration and intensity of neoadjuvant chemotherapy further improved survival compa

146 Patients receiving neoadjuvant chemotherapy had more advanced disease at ba

147 mors that demonstrated a good response after neoadjuvant chemotherapy had significantly lower (18)F-F

148 the rate of breast-conserving surgery after neoadjuvant chemotherapy has not been well studied.

149 r survival, such as pathological response to neoadjuvant chemotherapy, has the potential to improve t

150 trates that breast cancer patients receiving neoadjuvant chemotherapy have no increased risk for surg

151 adjusted for baseline staging, smoking, and neoadjuvant chemotherapy (hazard ratio, 2.03; 95% CI, 1.

152 ical trials evaluating patients treated with neoadjuvant chemotherapy in borderline-resectable and lo

153 eases (P = .001) in mean Hb(T) levels during neoadjuvant chemotherapy in breast abnormality ROIs for

154 predicts better response to PTX/CBP regimen neoadjuvant chemotherapy in breast cancer patients, who

155 tumor response prediction after 2 cycles of neoadjuvant chemotherapy in breast cancer.

156 luate cyclin E as a predictor of response to neoadjuvant chemotherapy in breast cancer.

157 iated with pathological complete response to neoadjuvant chemotherapy in ER-negative disease, suggest

158 and safety of adding bevacizumab to standard neoadjuvant chemotherapy in HER2-negative early breast c

159 re on outcomes and pathologic findings after neoadjuvant chemotherapy in IRSS stage III retinoblastom

160 the primary tumour that predict response to neoadjuvant chemotherapy in liver metastases.

161 urtosis appears to be associated with pCR to neoadjuvant chemotherapy in non-triple-negative breast c

162 Chemotherapy, and neoadjuvant chemotherapy in particular, was given more f

163 assessing sentinel lymph node surgery after neoadjuvant chemotherapy in patients presenting with nod

164 During neoadjuvant chemotherapy in patients with breast cancer,

165 overall survival (OS) after response-guided neoadjuvant chemotherapy in patients with early breast c

166 es), and the safety of adding bevacizumab to neoadjuvant chemotherapy in patients with early-stage br

167 n in the primary tumour predicts response to neoadjuvant chemotherapy in the liver metastases, and in

168 Our data merit further research into neoadjuvant chemotherapy in the setting of CRS and HIPEC

169 f data exploring the benefits of adjuvant or neoadjuvant chemotherapy in the treatment of breast canc

170 ature was associated with better response to neoadjuvant chemotherapy in TNBC (P < 0.0001) but not in

171 and a predictive marker for the response to neoadjuvant chemotherapy in TNBC, implying a potential r

172 with sentinel lymph node (SLN) surgery after neoadjuvant chemotherapy in women presenting with node-p

173 receptor 2 (HER2) -targeting drugs added to neoadjuvant chemotherapy increased pathologic complete r

174 ctDNA detection at the end of neoadjuvant chemotherapy indicated significantly worse r

175 gnosis rather than the clinical stage before neoadjuvant chemotherapy, indicating the importance of f

176 Although neoadjuvant chemotherapy is a standard component of brea

177 Neoadjuvant chemotherapy is among variables identified a

178 Neoadjuvant chemotherapy is associated with lower overal

179 Before neoadjuvant chemotherapy is delivered, all patients shou

180 Neoadjuvant chemotherapy is established in the managemen

181 Neoadjuvant chemotherapy is given more frequently to bla

182 clinical interest of axillary staging after neoadjuvant chemotherapy is increasing and this approach

183 ome sequencing of samples obtained following neoadjuvant chemotherapy is representative of the genomi

184 should remain the regimen to choose whenever neoadjuvant chemotherapy is used in patients with high-r

185 rcinomas, and although it responds poorly to neoadjuvant chemotherapy, it appears to respond well to

186 al after receiving taxane plus anthracycline neoadjuvant chemotherapy (MD Anderson-NeoACT: HR 0.68, 9

187 atory analysis suggests that response-guided neoadjuvant chemotherapy might improve survival and is m

188 nd analyzed for outcome (n=536), response to neoadjuvant chemotherapy (n=125) and platinum resistance

189 ieve pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) and which will have resid

190 rly changes in (18)F-FDG tumor uptake during neoadjuvant chemotherapy (NAC) can predict outcomes.

191 The increasing use of neoadjuvant chemotherapy (NAC) for operable breast cance

192 Treatment with neoadjuvant chemotherapy (NAC) has made it possible for

193 for sentinel lymph node (SLN) surgery after neoadjuvant chemotherapy (NAC) in cN1 disease.

194 from two phase II clinical trials evaluating neoadjuvant chemotherapy (NAC) in PDAC.

195 Response to neoadjuvant chemotherapy (NAC) in triple negative breast

196 Neoadjuvant chemotherapy (NAC) induces a pathological co

197 Pathologic downstaging (pDS) to neoadjuvant chemotherapy (NAC) is one of the most import

198 t of rising bilateral mastectomy rates among neoadjuvant chemotherapy (NAC) recipients in California.

199 sist in predicting treatment response in the neoadjuvant chemotherapy (NAC) setting.

200 The mean tumour size before neoadjuvant chemotherapy (NAC) was 4.21 +/- 0.99 cm and

201 -FDG PET/CT performed at baseline and during neoadjuvant chemotherapy (NAC) was able to early depict

202 trial to evaluate the efficacy and safety of neoadjuvant chemotherapy (NAC) with cisplatin and gemcit

203 tween PTGS2 expression, celecoxib use during neoadjuvant chemotherapy (NAC), and both event-free surv

204 To elucidate the effects of neoadjuvant chemotherapy (NAC), we conduct whole transcr

205 onse (pCR) in women undergoing breast cancer neoadjuvant chemotherapy (NAC).

206 e response (pCR) of primary breast cancer to neoadjuvant chemotherapy (NAC).

207 axillary pathologic complete response after neoadjuvant chemotherapy (NAC).

208 associated with multi-drug resistance to the neoadjuvant chemotherapy (NAC).

209 CR) and recurrence-free survival (RFS) after neoadjuvant chemotherapy (NAC).

210 strates a pathologic tumor response (pTR) to neoadjuvant chemotherapy (NAC).

211 DG PET/CT imaging for pathologic response to neoadjuvant chemotherapy (NACT) and outcome in inflammat

212 dvanced ovarian cancer who were treated with neoadjuvant chemotherapy (NACT) compared with primary cy

213 ts of primary cytoreductive surgery (PCS) vs neoadjuvant chemotherapy (NACT) for advanced-stage epith

214 umor-immune interface at baseline and during neoadjuvant chemotherapy (NACT) in high-grade serous ova

215 In neoadjuvant chemotherapy (NACT) pathological complete re

216 ologic complete response (pCR) with standard neoadjuvant chemotherapy (NACT).

217 high grade serous ovarian cancer (HGSOC) to neoadjuvant chemotherapy (NACT).

218 ctors of locoregional recurrence (LRR) after neoadjuvant chemotherapy (NC) has resulted in controvers

219 Neoadjuvant chemotherapy (NC) is increasingly being used

220 y if percutaneous biopsy of the breast after neoadjuvant chemotherapy (NCT) indicates pCR in the brea

221 esponse in breast cancer patients undergoing neoadjuvant chemotherapy (NCT).

222 Neither neoadjuvant chemotherapy nor routine surgery is needed t

223 treatment involving radical cystectomy with neoadjuvant chemotherapy offers the best chance for cure

224 Neoadjuvant chemotherapy often yields a partial response

225 staging system for assessing prognosis after neoadjuvant chemotherapy on the basis of pretreatment cl

226 Selecting patients for neoadjuvant chemotherapy on the basis of risk of node-po

227 horoid and optic nerve, decision in favor of neoadjuvant chemotherapy on the basis of suspected postl

228 equired to make definitive conclusions about neoadjuvant chemotherapy, onset of PMs, and mucinous his

229 ially resectable disease, may receive either neoadjuvant chemotherapy or primary cytoreductive surger

230 y on the right lobe of the liver (OR = 1.6), neoadjuvant chemotherapy (OR = 2), and a transverse subc

231 ight loss, higher ASA-score, higher N-stage, neoadjuvant chemotherapy, or no neoadjuvant therapy (com

232 of individual patient data from prospective neoadjuvant chemotherapy osteosarcoma studies and regist

233 predicted pathological complete responses to neoadjuvant chemotherapy (P < 0.001) with high expressio

234 95% CI, 91-95) and 90% (95% CI, 87-93) after neoadjuvant chemotherapy (P < 0.001)].

235 EBL were trans-anastomotic stent placement, neoadjuvant chemotherapy, pancreaticogastrostomy reconst

236 The patient had multiple concerns regarding neoadjuvant chemotherapy, particularly toxicities, espec

237 In patients without neoadjuvant chemotherapy, pathologic size of index malig

238 between metabolic response after 2 cycles of neoadjuvant chemotherapy, pCR, and outcome in patients r

239 at baseline (PET/CT-1) and after 3 cycles of neoadjuvant chemotherapy (PET/CT-2).

240 and distant progression after 2-4 cycles of neoadjuvant chemotherapy plus RHT for STS.

241 d adaptive randomization to compare standard neoadjuvant chemotherapy plus the tyrosine kinase inhibi

242 t of disease at presentation and response to neoadjuvant chemotherapy predict the risk of locoregiona

243 Neoadjuvant chemotherapy prevented orbital exenterations

244 urvival was strongly dictated by stage after neoadjuvant chemotherapy, rather than clinical stage at

245 Neoadjuvant chemotherapy reduces the need for axillary l

246 I or II breast cancer receiving adjuvant or neoadjuvant chemotherapy regimens excluding sequential o

247 ing neoadjuvant plus adjuvant bevacizumab to neoadjuvant chemotherapy regimens would also improve out

248 Although neoadjuvant chemotherapy remains the preferred approach

249 ed the role of (18)F-FDG PET/CT for staging, neoadjuvant chemotherapy response evaluation, and final

250 5 breast cancer patients with information on neoadjuvant chemotherapy responses.

251 n women with breast cancer who are receiving neoadjuvant chemotherapy show a mean decrease in Hb(T) w

252 The addition of bevacizumab to neoadjuvant chemotherapy significantly increased the rat

253 The addition of bevacizumab to neoadjuvant chemotherapy significantly increased the rat

254 for resistance and response to preoperative (neoadjuvant) chemotherapy (stratified according to ER st

255 ression was reduced among women who received neoadjuvant chemotherapy, suggesting a role for chemothe

256 10% or less residual viable tumour after neoadjuvant chemotherapy, termed here major pathological

257 mor regression score in NSCLC patients under neoadjuvant chemotherapy than algorithms and methods usi

258 tratifies patients with respect to LRR after neoadjuvant chemotherapy than presenting clinical stage

259 spite level I evidence supporting the use of neoadjuvant chemotherapy, there remains disagreement reg

260 In patients treated with neoadjuvant chemotherapy, TLS density was similar, but G

261 Patients were treated with neoadjuvant chemotherapy, transthoracic esophagectomy, a

262 Molecular analysis of the tumor stroma in neoadjuvant chemotherapy-treated human desmoplastic canc

263 ptical imaging method on the first day after neoadjuvant chemotherapy treatment can discriminate nonr

264 Such patients are excluded from neoadjuvant chemotherapy trials and pooled with patients

265 of this study was to determine variations in neoadjuvant chemotherapy use in a large multi-center nat

266 quisition to monitor breast tumor DeltaBF to neoadjuvant chemotherapy using (18)F-FDG PET/CT.

267 mor pathology) for assessing prognosis after neoadjuvant chemotherapy using pretreatment clinical sta

268 d, phase 3 trials, evaluation of response to neoadjuvant chemotherapy using Response Evaluation Crite

269 and previous treatment (previous adjuvant or neoadjuvant chemotherapy vs none).

270 Neoadjuvant chemotherapy was able to avoid exenteration

271 Neoadjuvant chemotherapy was administered to 577 patient

272 Neoadjuvant chemotherapy was associated with decreased o

273 line staging, age, comorbidity, smoking, and neoadjuvant chemotherapy was higher (hazard ratio, 3.39;

274 Use of neoadjuvant chemotherapy was not significant when added

275 data on both types of scan before and after neoadjuvant chemotherapy were analyzed regarding SUVmax,

276 y and tumor in the optic nerve cut end after neoadjuvant chemotherapy were associated with inferior o

277 ction of additional lesions in women without neoadjuvant chemotherapy were compared.

278 The scheduling of surgery and use of neoadjuvant chemotherapy were determined by local multid

279 who underwent liver resection for CRLM after neoadjuvant chemotherapy were evaluated.

280 nd their variation (Delta) after 2 cycles of neoadjuvant chemotherapy were extracted from the PET ima

281 , 28-82 years; mean age, 49 years) receiving neoadjuvant chemotherapy were monitored with 3.0-T MR im

282 negative breast cancer and an indication for neoadjuvant chemotherapy were prospectively included.

283 Patients who were eligible for neoadjuvant chemotherapy were recruited between December

284 Among women with cN1 breast cancer receiving neoadjuvant chemotherapy who had 2 or more SLNs examined

285 ents with a clinical complete response after neoadjuvant chemotherapy who have been managed by a watc

286 enrolled in a prospective study and received neoadjuvant chemotherapy with anthracyclines, taxanes, o

287 assess the safety and long-term efficacy of neoadjuvant chemotherapy with capecitabine and oxaliplat

288 umstances, the AHOPCA II protocol introduced neoadjuvant chemotherapy with delayed enucleation.

289 e addition of capecitabine or gemcitabine to neoadjuvant chemotherapy with docetaxel, followed by dox

290 She received neoadjuvant chemotherapy with doxorubicin plus cyclophos

291 tion (LVEF) >/= 55% at study entry following neoadjuvant chemotherapy with or without radiotherapy.

292 Neoadjuvant chemotherapy with or without second-look sur

293 This phase II trial evaluated the effect of neoadjuvant chemotherapy with or without second-look sur

294 )F-FDG PET/CT before and after 2-4 cycles of neoadjuvant chemotherapy with RHT for STS.

295 l after immediate primary surgery, or before neoadjuvant chemotherapy with subsequent planned delayed

296 We performed a phase II study of neoadjuvant chemotherapy with the objective of determini

297 Neoadjuvant chemotherapy with trastuzumab for patients w

298 or extensive residual disease (n = 11) after neoadjuvant chemotherapy, with cases from The Cancer Gen

299 ched propensity analysis was performed using neoadjuvant chemotherapy within 30 days of surgery as tr

300 ollowed by doxorubicin plus cyclophosphamide neoadjuvant chemotherapy would improve outcomes in women